Pantethine

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Summary

Pantethine is a naturally occurring compound derived from panthothenic acid. It acts as an intermediate in endogenous coenzyme A synthesis and is used as a dietary supplement to treat hypertriglyceridemia.

Generic Name
Pantethine
DrugBank Accession Number
DB11190
Background

Pantethine is a naturally occurring compound synthesized in the body from pantothenic acid (vitamin B5) via addition of cysteamine. It consists of two molecules of pantetheine that form a dimer via disufide linkages, and acts as an intermediate in the production of Coenzyme A. Coenzyme A plays an essential role as a cofactor in the metabolism of lipids and carbohydrates including fatty acid oxidation, carbohydrate metabolism, pyruvate degradation, and amino acid catabolism 2. Pantethine is available as a dietary supplement for lowering blood cholesterol and triglycerides.

Type
Small Molecule
Groups
Approved, Investigational
Structure
Weight
Average: 554.721
Monoisotopic: 554.24440572
Chemical Formula
C22H42N4O8S2
Synonyms
  • Bis(pantothenamidoethyl) disulfide
  • D-Bis(N-pantothenyl-beta-aminoethyl) disulfide
  • D-pantethine
  • Pantethine
  • Pantetina
  • Pantomin

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Indication TypeIndicationCombined Product DetailsApproval LevelAge GroupPatient CharacteristicsDose Form
Management ofHypertriglyceridemias•••••••••••••••••••
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
No interactions found.

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
PuralorPantethine (2.5 mg/1) + 1-(c14-c18 esteroyl)-2-docosahexanoyl-sn-glycero-3-phosphocholine (5 mg/1) + 1-(c14-c18 esteroyl)-2-docosahexanoyl-sn-glycero-3-phosphoethanolamine (2.5 mg/1) + Acetylcysteine amide (5 mg/1) + Ascorbic acid (25 mg/1) + Cholecalciferol (100 [iU]/1) + Citric acid (1.6 mg/1) + Cobamamide (2 mg/1) + Egg phospholipids (42.5 mg/1) + Folic acid (42.5 mg/1) + Gastric intrinsic factor (2.5 mg/1) + Magnesium L-threonate (2.5 mg/1) + Leucovorin (3 mg/1) + Levomefolic acid (0.4 mg/1) + Magnesium glycinate (1 mg/1) + Niacin (0.5 mg/1) + Papain (20 mg/1) + Riboflavin (0.5 mg/1) + Sodium citrate (0.8 mg/1) + Thiamine chloride (0.5 mg/1)Tablet, chewableOralCenturion Labs2014-01-012017-09-20US flag

Categories

ATC Codes
A11HA32 — Pantethine
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as beta amino acids and derivatives. These are amino acids having a (-NH2) group attached to the beta carbon atom.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Carboxylic acids and derivatives
Sub Class
Amino acids, peptides, and analogues
Direct Parent
Beta amino acids and derivatives
Alternative Parents
N-acyl amines / Monosaccharides / Secondary carboxylic acid amides / Secondary alcohols / Dialkyldisulfides / Sulfenyl compounds / Primary alcohols / Organopnictogen compounds / Organonitrogen compounds / Organic oxides
show 2 more
Substituents
Alcohol / Aliphatic acyclic compound / Beta amino acid or derivatives / Carbonyl group / Carboxamide group / Dialkyldisulfide / Fatty acyl / Fatty amide / Hydrocarbon derivative / Monosaccharide
show 13 more
Molecular Framework
Aliphatic acyclic compounds
External Descriptors
organic disulfide (CHEBI:31959)
Affected organisms
Not Available

Chemical Identifiers

UNII
7K81IL792L
CAS number
16816-67-4
InChI Key
DJWYOLJPSHDSAL-ROUUACIJSA-N
InChI
InChI=1S/C22H42N4O8S2/c1-21(2,13-27)17(31)19(33)25-7-5-15(29)23-9-11-35-36-12-10-24-16(30)6-8-26-20(34)18(32)22(3,4)14-28/h17-18,27-28,31-32H,5-14H2,1-4H3,(H,23,29)(H,24,30)(H,25,33)(H,26,34)/t17-,18-/m0/s1
IUPAC Name
(2R)-N-[2-({2-[(2-{3-[(2R)-2,4-dihydroxy-3,3-dimethylbutanamido]propanamido}ethyl)disulfanyl]ethyl}carbamoyl)ethyl]-2,4-dihydroxy-3,3-dimethylbutanamide
SMILES
CC(C)(CO)[C@@H](O)C(=O)NCCC(=O)NCCSSCCNC(=O)CCNC(=O)[C@H](O)C(C)(C)CO

References

General References
  1. Evans M, Rumberger JA, Azumano I, Napolitano JJ, Citrolo D, Kamiya T: Pantethine, a derivative of vitamin B5, favorably alters total, LDL and non-HDL cholesterol in low to moderate cardiovascular risk subjects eligible for statin therapy: a triple-blinded placebo and diet-controlled investigation. Vasc Health Risk Manag. 2014 Feb 27;10:89-100. doi: 10.2147/VHRM.S57116. eCollection 2014. [Article]
  2. Horvath Z, Vecsei L: Current medical aspects of pantethine. Ideggyogy Sz. 2009 Jul 30;62(7-8):220-9. [Article]
Human Metabolome Database
HMDB0003828
KEGG Drug
D01234
KEGG Compound
C12661
PubChem Compound
452306
PubChem Substance
347827940
ChemSpider
398402
RxNav
32863
ChEBI
31959
ChEMBL
CHEMBL2104786
ZINC
ZINC000003874604
Wikipedia
Pantethine

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3CompletedTreatmentHyperlipoproteinemia (a)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Capsule
Tablet, chewableOral
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.117 mg/mLALOGPS
logP-0.25ALOGPS
logP-3.4Chemaxon
logS-3.7ALOGPS
pKa (Strongest Acidic)12.38Chemaxon
pKa (Strongest Basic)-2.8Chemaxon
Physiological Charge0Chemaxon
Hydrogen Acceptor Count8Chemaxon
Hydrogen Donor Count8Chemaxon
Polar Surface Area197.32 Å2Chemaxon
Rotatable Bond Count19Chemaxon
Refractivity139.83 m3·mol-1Chemaxon
Polarizability59.42 Å3Chemaxon
Number of Rings0Chemaxon
Bioavailability0Chemaxon
Rule of FiveNoChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSsplash10-0udi-2911110000-ee07e9becfed637be16d
MS/MS Spectrum - Quattro_QQQ 10V, NegativeLC-MS/MSsplash10-0fb9-0090070000-35b025334d19a78599dd
MS/MS Spectrum - Quattro_QQQ 25V, NegativeLC-MS/MSsplash10-004i-0290000000-7ca01ded1653a62128e1
MS/MS Spectrum - Quattro_QQQ 40V, NegativeLC-MS/MSsplash10-0002-1910000000-0861914df9680af5585f
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-0570-0000950000-12c3c653d4e08fd3fb7d
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-0ufr-0050090000-73d18dfc064767369751
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-0abi-0011910000-5d90a0f1da1b1e982311
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-004i-0190010000-889010bf92a2b90d7f94
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-00di-0256910000-28af9f73434fbf9ad357
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-0006-9444230000-465989f988553a479bbb
1H NMR Spectrum1D NMRNot Applicable
[1H,13C] 2D NMR Spectrum2D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-209.3810944
predicted
DarkChem Lite v0.1.0
[M-H]-233.7560944
predicted
DarkChem Lite v0.1.0
[M-H]-215.53885
predicted
DeepCCS 1.0 (2019)
[M+H]+210.0387944
predicted
DarkChem Lite v0.1.0
[M+H]+229.0530944
predicted
DarkChem Lite v0.1.0
[M+H]+217.89685
predicted
DeepCCS 1.0 (2019)
[M+Na]+222.2208944
predicted
DarkChem Lite v0.1.0
[M+Na]+230.9270944
predicted
DarkChem Lite v0.1.0
[M+Na]+223.99
predicted
DeepCCS 1.0 (2019)

Drug created at December 03, 2015 16:51 / Updated at May 21, 2021 10:21